Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Australia not worried about vaccine trial pause, cases rise in hot spot

Published 09/08/2020, 06:41 PM
Updated 09/08/2020, 09:15 PM
© Reuters. FILE PHOTO:  Disinfectant products are seen on a car whilst motorists fill out paperwork for police as they cross back into South Australia from Victoria during the coronavirus disease (COVID-19) outbreak, in Bordertown

By Renju Jose

SYDNEY (Reuters) - Australia is not worried about AstraZeneca (NYSE:AZN) Plc's decision to put on hold its COVID-19 vaccine trial, its deputy chief medical officer said on Wednesday, as daily cases nudged higher in the country's coronavirus hot spot.

AstraZeneca on Tuesday said it has paused a late-stage trial of one of the leading COVID-19 vaccine candidates after an unexplained illness in a study participant.

The nature of the case and when it happened were not detailed, although the participant is expected to recover, according to Stat News, which first reported the news.

"With the information that I have got at the moment, I am not worried about it," Australia's Deputy Chief Medical Officer Nick Coatsworth told Sky News, adding the hold on trials does not mean the vaccine "is off the table".

"In some respects, this is a very positive thing because it shows that despite the accelerated vaccine development, safety is the priority of the clinical trialists and investigators."

Coatsworth said Australia like many other governments has invested in several coronavirus vaccine candidates, "knowing not all of them will get through".

AstraZeneca's decision to place the trial on hold comes after a pledge from nine leading U.S. and European vaccine developers on Tuesday to uphold scientific safety and efficacy standards for their vaccines despite the urgency to contain the pandemic.

Australia on Monday said it would get the first doses of AstraZeneca's vaccine in January 2021 if trials proved successful after reaching a preliminary deal in August.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

It had also signed an agreement on a COVID-19 vaccine being developed by the University of Queensland. Both these vaccines will be manufactured locally by CSL (OTC:CSLLY) Ltd.

Australia's coronavirus hot spot of Victoria on Wednesday, meanwhile, reported its biggest rise in daily cases in three days as the state boosted its contact tracing programme to ease the spread of the virus.

Victoria, which is at the centre of Australia's second wave of coronavirus outbreak, now accounts for about 75% of Australia's 26,450 COVID-19 cases and 90% of its 781 deaths.

The state reported 76 new cases and 11 deaths from the virus in the last 24 hours.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.